A New Augmentation Strategy against Depression Combining SSRIs and the N-terminal Fragment of Galanin (1-15).

IF 4.8 2区医学 Q1 NEUROSCIENCES

Current Neuropharmacology Pub Date : 2024-10-31 DOI:10.2174/1570159X23666241003125019

Antonio Flores-Burgess, Carmelo Millón, Noelia Cantero-García, Juan Pedro Pineda-Gómez, Marta Flores-Gómez, Zaida Díaz-Cabiale

引用次数: 0

Abstract

Depression is one of the most disabling mental disorders, with the second highest social burden; its prevalence has grown by more than 27% in recent years, affecting 246 million in 2021. Despite the wide range of antidepressants available, more than 50% of patients show treatment-resistant depression. In this review, we summarized the progress in developing a new augmentation strategy based on combining the N-terminal fragment of Galanin (1-15) and SSRI-type antidepressants in animal models.

查看原文本刊更多论文

结合 SSRIs 和 Galanin (1-15) N 端片段的抗抑郁新策略。

抑郁症是致残率最高的精神疾病之一，也是社会负担第二重的疾病；近年来，其发病率增长了 27% 以上，2021 年将有 2.46 亿人受到影响。尽管抗抑郁药物种类繁多，但仍有 50%以上的抑郁症患者表现出耐药性。在这篇综述中，我们总结了在动物模型中开发一种新的增强策略的进展情况，这种策略是基于加兰宁（1-15）的N端片段和SSRI类抗抑郁药的结合。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Neuropharmacology 医学-神经科学

CiteScore

8.70

自引率

1.90%

发文量

369

审稿时长

>12 weeks

期刊介绍： Current Neuropharmacology aims to provide current, comprehensive/mini reviews and guest edited issues of all areas of neuropharmacology and related matters of neuroscience. The reviews cover the fields of molecular, cellular, and systems/behavioural aspects of neuropharmacology and neuroscience. The journal serves as a comprehensive, multidisciplinary expert forum for neuropharmacologists and neuroscientists.